Advancing Drug Development with Emerging Technologies

February 3, 2022 PAO-02-22-R250-03

On the last day of the Road to 50 States road trip campaign, Simon Edwards, Global Head of Sales for Biologics at Lonza, talks to Nigel in his backyard about the emergence of artificial intelligence and how it can help accelerate drug selection and development going forward.

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare, and life science industries. Lonza produces and supports active pharmaceutical ingredients (APIs) both chemically as well as biotechnologically. The company has capabilities in large and small molecules, peptides, amino acids, and niche bioproducts, which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based research, endotoxin detection, and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro, and personal care markets.

Q: